Addition of the SHP-2 inhibitor SHP099 to radio-immunotherapy (RT 3 × 12 Gy + anti-PD-1 antibody) improved the anti-tumor response in an anti-PD-1 antibody-resistant lung cancer model [56]. Here, PDCD1 is linked to lung cancer.